Administration of oral medicinal products as crushed tablets or open capsules is an important delivery option for patients suffering from dysphagia. To obtain full interchangeability of generics with the original products, demonstration of bioequivalence (BE) between both products administered as crushed tablets/open capsules was required for poorly soluble product by European Medicines Agency (EMA) at the time of development of our rivaroxaban and deferasirox generic products. We present the results of two BE studies with modified administration of these products, which compared relative bioavailability between generic and reference products. In the rivaroxaban study, the test product was administered as a capsule sprinkled on and mixed with applesauce, whereas the reference tablet was crushed and administered with applesauce under fed conditions. In the deferasirox study, both treatments were administered as crushed tablets under fasting conditions. Both studies applied a two-way crossover design and were conducted after a single-dose in healthy volunteers. The 90% confidence interval of the geometric mean ratio area under the analyte concentration versus time curve, from time zero to the time of the last measurable analyte concentration and maximum measured analyte concentration over the sampling period of the test to reference ratio were 103.36-110.37% and 97.98-108.45% for rivaroxaban, respectively, and 96.69-107.29% and 94.19-109.45% for deferasirox, respectively. Thus, the BE criteria (80.00-125.00%) were met in both studies which demonstrated that bioavailability was not affected when the test and reference products were administered in the form of crushed tablet/open capsule. These results support the argument of redundancy of crushed product studies for poorly soluble drugs, which is in line with the currently revised position of the EMA on this topic.

Zentiva k s Prague Czech Republic

Zobrazit více v PubMed

Doan TN, Ho WC, Wang LH, Chang FC, Nhu NT, Chou LW. Prevalence and methods for assessment of oropharyngeal dysphagia in older adults: a systematic review and meta‐analysis. J Clin Med. 2022;11(9):1‐14. doi:10.3390/jcm11092605 PubMed DOI PMC

Cho SY, Choung RS, Saito YA, et al. Prevalence and risk factors for dysphagia: a USA community study. Neurogastroenterol Motil. 2015;27(2):212‐219. doi:10.1111/nmo.12467 PubMed DOI PMC

Suttrup I, Warnecke T. Dysphagia in Parkinson's disease. Dysphagia. 2016;31(1):24‐32. doi:10.1007/s00455-015-9671-9 PubMed DOI

Aghaz A, Alidad A, Hemmati E, Jadidi H, Ghelichi L. Prevalence of dysphagia in multiple sclerosis and its related factors: systematic review and meta‐analysis. Iran J Neurol. 2018;17(4):180‐188. PubMed PMC

Espinosa‐Val MC, Martin‐Martinez A, Graupera M, et al. Prevalence, risk factors, and complications of oropharyngeal dysphagia in older patients with dementia. Nutrients. 2020;12(3):1‐15. doi:10.3390/nu12030863 PubMed DOI PMC

Rajati F, Ahmadi N, Naghibzadeh ZA, Kazeminia M. The global prevalence of oropharyngeal dysphagia in different populations: a systematic review and meta‐analysis. J Transl Med. 2022;20(1):175. doi:10.1186/s12967-022-03380-0 PubMed DOI PMC

Hansen TS, Engberg AW, Larsen K. Functional oral intake and time to reach unrestricted dieting for patients with traumatic brain injury. Arch Phys Med Rehabil. 2008;89(8):1556‐1562. doi:10.1016/j.apmr.2007.11.063 PubMed DOI

Bremare A, Rapin A, Veber B, Beuret‐Blanquart F, Verin E. Swallowing disorders in severe brain injury in the arousal phase. Dysphagia. 2016;31(4):511‐520. doi:10.1007/s00455-016-9707-9 PubMed DOI

Batista AO, Nascimento WV, Cassiani RA, et al. Prevalence of non‐obstructive dysphagia in patients with heartburn and regurgitation. Clinics (Sao Paulo). 2020;75:e1556. doi:10.6061/clinics/2020/e1556 PubMed DOI PMC

Rollini F, Franchi F, Hu J, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol. 2016;67(17):1994‐2004. doi:10.1016/j.jacc.2016.02.045 PubMed DOI

Balch RJ, Trescot A. Extended‐release morphine sulfate in treatment of severe acute and chronic pain. J Pain Res. 2010;3:191‐200. doi:10.2147/JPR.S6529 PubMed DOI PMC

Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27‐37. doi:10.5009/gnl15502 PubMed DOI PMC

Aparisi L, Rodrigo JM, Serra MA, Del Olmo J, Bisquert M, Raga F. Efficacy of a new microencapsulated pancreatin versus a conventional preparation, in the treatment of steatorrhea of pancreatic origin. Rev Esp Enferm Apar Dig. 1989;76(1):25‐30. PubMed

Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5‐aminosalicylic acid. Clin Pharmacokinet. 1985;10(4):285‐302. doi:10.2165/00003088-198510040-00001 PubMed DOI

Li Z, Wang Z, Shen B, Chen C, Ding X, Song H. Effects of aspirin on the gastrointestinal tract: pros vs. cons. Oncol Lett. 2020;20(3):2567‐2578. doi:10.3892/ol.2020.11817 PubMed DOI PMC

Abraham SC, Cruz‐Correa M, Lee LA, Yardley JH, Wu TT. Alendronate‐associated esophageal injury: pathologic and endoscopic features. Mod Pathol. 1999;12(12):1152‐1157. PubMed

Liu DT, Besser G, Oeller F, Mueller CA, Renner B. Bitter taste perception of the human tongue mediated by quinine and caffeine impregnated taste strips. Ann Otol Rhinol Laryngol. 2020;129(8):813‐820. doi:10.1177/0003489420906187 PubMed DOI PMC

Karaman R. Prodrugs for masking bitter taste of antibacterial drugs—a computational approach. J Mol Model. 2013;19(6):2399‐2412. doi:10.1007/s00894-013-1780-5 PubMed DOI

de Vries H, Beijersbergen van Henegouwen GM. Photoreactivity of nifedipine in vitro and in vivo. J Photochem Photobiol B. 1998;43(3):217‐221. doi:10.1016/s1011-1344(98)00111-0 PubMed DOI

Summary of Product Characteristics, Xarelto 20 mg film‐coated tablets. Bayer AG. 2009. Accessed January 29, 2024.

Summary of product characteristics, Exjade 360 mg, film‐coated tablets. Novartis Europharm Limited. 2009. Accessed January 29, 2024.

Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1‐16. doi:10.1007/s40262-013-0100-7 PubMed DOI PMC

Yan Song PMC, Akiyuki Suzuki M, Robert JA, et al. Evaluation of crushed tablet for Oral administration and the effect of food on apixaban pharmacokinetics in healthy adults. Clin Ther. 2016;38:1674‐1685. PubMed

European Medicines Agency . Clinical pharmacology and pharmacokinetics: questions and answers. European Medicines Agency; 2019.